Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: Phase II trial of the North Central Cancer Treatment Group

Journal of Thoracic Oncology

Volumn 1, Issue 3, 2006, Pages 211-217

  Dy, Grace K ^a   Jett, James R ^a   Geoffroy, Francois J ^b   Krewer, Keith D ^c   Tazelaar, Henry ^a   Maurer, Matthew ^a   Rowland, Kendrith ^d   Mailliard, James ^e   Krook, James ^f   Dakhil, Shaker ^g   Kutteh, Leila ^c   Kugler, John ^b   Wender, Donald ^h  

^a MAYO CLINIC   (United States)

^b Illinois Oncol Res Assoc CCOP   (United States)

^c Cedar Rapids Oncology Project CCOP   (United States)

^d Carle Cancer Center CCOP   (United States)

^e MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^f Duluth CCOP   (United States)

^g WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^h Siouxland Hematology Oncology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG TOLERANCE; DYSPNEA; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; BRAIN TUMOR; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; KAPLAN MEIER METHOD; LUNG TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; SMALL CELL CARCINOMA; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, SMALL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; PACLITAXEL; SURVIVAL RATE; TOPOTECAN;

EID: 34247890134     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/S1556-0864(15)31570-7     Document Type: Article

References (32)

1. Laskin J, Sandler A, Johnson DH. An advance in small-cell lung cancer treatment: More or less. J Natl Cancer Inst 2003;95:1099-1101.
2. Jett JR, Maksymiuk AW, Su JQ, et al. Phase III trial of recombinant interferon gamma in complete responders with small cell lung cancer. J Clin Oncol 1994;12:2321-2326.
3. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.
4. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-291.
5. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997;15:2090-2096.
6. Depierre A, von Pawel J, Hans K, et al. Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC): A multicentre phase II study. Lung Cancer 1997;18 (Suppl 1):35.
7. Eckardt J, Gralla R, Palmer MC, et al. Topotecan (T) as second-line therapy in patients (Pts) with small cell lung cancer (SCLC): A phase II study. Ann Oncol 1996;7 (Suppl 5):107.
8. Schiller JH, Kim KM, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group Trial. J Clin Oncol 1996;14:2345-2352.
9. Ardizzoni A. Topotecan in the treatment of recurrent small cell lung cancer: An update. The Oncologist 2004;9 (Suppl 6):4-13.
10. Perez-Soler R, Glisson BS, Lee JS, et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with topoisomerase I poison topotecan. J Clin Oncol 1996;14:2785-2790.
11. Takeda K, Negoro S, Sawa T, et al. A phase II study of topotecan in patients with relapsed small-cell lung cancer. Clin Lung Cancer 2003;4:224-228.
12. Ettinger DS, Finkelstein DM, Sarma RP, et al. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 1995;13:1430-1435.
13. Kirschling RJ, Grill JP, Marks RS, et al. Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: A phase II study of the North Central Cancer Treatment Group. Am J Clin Oncol 1999;22:517-522.
14. Bahadori HR, Green MR, Catapano CV. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother Pharmacol 2001;48:188-196.
15. Jonsson E, Fridborg H, Nygren P, et al. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol 1998;54:509-514.
16. Ramalingam S, Belani CP, Day R, et al. Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer. Ann Oncol 2004;15:247-251.
17. Lyss AP, Herndon JE II, Lynch TJ Jr, et al. Novel doublets in extensive-stage small-cell lung cancer: A randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). Clin Lung Cancer 2002;3:205-210.
18. Tweedy CR, Andrews DF, Ball T. Topotecan and paclitaxel in extensive stage small cell lung cancer as initial therapy (Abstract). Proc Am Soc Clin Oncol 1999;18:525.
19. Schütte W, Bork I, Öhlmann K, et al. Phase II study: First line treatment of stage IV small cell lung cancer with topotecan and paclitaxel (Abstract). Proc Am Soc Clin Oncol 2001;20:283b.
20. Hainsworth JD, Gray JR, Stroup SL, et al. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: Comparison of sequential phase II trials using different dose-intensities. J Clin Oncol 1997;15:3464-3470.
21. Fields SZ, Eckardt JR, Zhang L, et al. Efficacy of reduced dose of IV topotecan in relapsed small cell lung cancer patients. Lung Cancer 2000;29 (Suppl. 1):10.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
23. Simon R. Optional two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
24. West W, Birch R, Schnell F, et al. Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer. The Oncologist 2003;8:76-82.
25. Groen HJ, Fokkema E, Biesma B, et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: A non-cross-resistant schedule. J Clin Oncol 1999;17:927-932.
26. Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractor or relapsed small cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003;21:1550-1555.
27. Hainsworth JD, Burris HA III, Erland JB, et al. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: A phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest 2003;21:193-199.
28. Johnson E, Lake D, Herndon JE II, et al. Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332. Am J Clin Oncol 2004;27:19-23.
29. Naka N, Kawahara M, Okishio K, et al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer 2002;37:319-323.
30. Ando M, Kobayashi K, Yoshimura A, et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 2004;44:121-127.
31. Goto K, Sekine I, Nishiwaki Y, et al. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br J Cancer 2004;91:659-665.
32. Ichiki M, Gohara R, Rikimaru T, et al. Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: A phase II study. Chemotherapy 2003;49:200-205.